Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$135.41 USD
-1.25 (-0.91%)
Updated May 31, 2024 04:00 PM ET
After-Market: $135.49 +0.08 (0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NBIX 135.41 -1.25(-0.91%)
Will NBIX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for NBIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NBIX
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
NBIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
Other News for NBIX
Neurocrine Biosciences to Participate at Investor Conferences in June
Oppenheimer Reaffirms Their Buy Rating on Neurocrine (NBIX)
Neurocrine Biosciences Announces CEO Succession Plan
Neurocrine Biosciences to Present New Phase 3 CAHtalystâ„¢ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
Key Takeaways From Neurocrine Biosciences Analyst Ratings